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Cancer in Iowa
2In 2003, an estimated 6,400 Iowans will die from cancer, 13 times the
number caused by auto fatalities. Cancer is second only to heart disease
as a cause of death. These projections are based upon mortality data
the State Health Registry of Iowa receives from the Iowa Department
of Public Health. The Registry has been recording the occurrence of
cancer in Iowa since 1973, and is one of fourteen registries nation-wide
providing data to the National Cancer Institute. With Cancer in Iowa:
2003 the Registry makes a general report to the public on the status of
cancer. This report will focus on:
• a description of the Registry and its goals;
• cancer projections for 2003;
• a special section on colorectal cancer;
• brief summaries of research projects during 2003;
• a selected list of publications from 2002.
3During 2003, the Registry will respond to 300 requests
           for data, analyses, and cancer cluster investigations.
The State Health Registry of Iowa
Cancer is a reportable disease as stated in the Iowa Administrative Code. Cancer data are collected by the
State Health Registry of Iowa, located at The University of Iowa in the College of Public Health’s Department
of Epidemiology. The staff includes more than 50 people. Half of them, situated throughout the state,
regularly visit hospitals, clinics, and medical laboratories in Iowa and neighboring states to collect cancer
data. In 2003 data will be collected on an estimated 14,700 new cancers among Iowa residents. A follow-up
program tracks more than 97 percent of the cancer survivors diagnosed since 1973. This program provides
regular updates for follow-up and survival. The Registry maintains the confidentiality of the patients,
physicians, and hospitals providing data.
Since 1973 the Iowa Registry has been funded by the Surveillance, Epidemiology, and End Results
(SEER) Program of the National Cancer Institute (NCI). Iowa represents rural and midwestern populations
and provides data included in many NCI publications. Beginning in 1990 about 5-10 percent of the Registry’s
annual operating budget has been provided by the state of Iowa. The Registry also receives funding through
grants and contracts with university, state, and national researchers investigating cancer-related topics.
The goals of the Registry are to:
• assemble and report measurements of cancer incidence, survival and mortality among Iowans;
• provide information on changes over time in the extent of disease at diagnosis, therapy, and patient survival;
• promote and conduct studies designed to identify factors relating to cancer etiology, prevention and control;
• respond to requests from individuals and organizations in the state of Iowa for cancer data and analyses;
• provide data and expertise for cancer research activities and educational opportunities.
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Cancer Projections for 2003
Estimated Number of New Cancers in Iowa for 2003
Estimated Number of Cancer Deaths in Iowa for 2003
In 2003, cancer will strike five out of every 1,000 Iowans. Cancer is the
second leading cause of death in Iowa, responsible for 2 of every 1,000 deaths.
     Breast, colon & rectum, lung, and prostate cancers will account
for more than half of all new cancers and cancer deaths.
5New Cancers in Females
Type # of Cancers % of Total
Breast 2200 30.1
Colon & Rectum 1100 15.1
Lung 870 11.9
Uterus 490 6.7
Non-Hodgkin’s Lymphoma 300 4.1
Ovary 250 3.4
Skin Melanoma 240 3.3
Leukemia 180 2.5
Kidney & Renal Pelvis 170 2.3
Pancreas 160 2.2
All Others 1340 18.4
Total 7300
New Cancers in Males
Type # of Cancers % of Total
Prostate 2200 29.7
Lung 1200 16.2
Colon & Rectum 1000 13.5
Non-Hodgkin’s Lymphoma 300 4.1
Skin Melanoma 280 3.8
Kidney & Renal Pelvis 280 3.8
Bladder 250 3.4
Leukemia 250 3.4
Oral Cavity 180 2.4
Pancreas 180 2.4
All Others 1280 17.3
Total 7400
Top 10 Types of Cancer in Iowa Estimated for 2003
Cancer Deaths in Females
Type # of Cancers  % of Total
Lung 700 22.6
Breast 450 14.5
Colon & Rectum 390 12.6
Ovary 190 6.1
Pancreas 180 5.8
Non-Hodgkin’s Lymphoma 150 4.8
Leukemia 120 3.9
Uterus 80 2.5
Brain 70 2.3
Multiple Myeloma 70 2.3
All Others 700 22.6
Total 3100
Cancer Deaths in Males
Type               # of Cancers % of Total
Lung 1000 30.3
Prostate 400 12.1
Colon & Rectum 350 10.6
Pancreas 160 4.9
Leukemia 160 4.9
Non-Hodgkin’s Lymphoma 150 4.6
Kidney & Renal Pelvis 120 3.6
Esophagus 100 3.0
Brain 90 2.7
Bladder 80 2.4
All Others 690 20.9
Total 3300
                Fortunately for Iowans, the chances of being diagnosed
     with many types of cancer can be reduced through positive health
           practices such as smoking cessation, physical exercise and
healthful dietary habits. Early detection through self-examination
     and regular health checkups can improve cancer survival.
6Cancer of the colon and rectum (colorectal cancer)
is the third most commonly diagnosed cancer and
the second leading cause of cancer deaths each year
in Iowa. Between 1973 and 2000, there were 58,783
colorectal cancers diagnosed in Iowa (Figure 1). Of
these, 95% were diagnosed in Iowans 50 years of age
and older. The number of colorectal cancers has
increased during this period from 1,840 per year in
the 1970s, to 2,180 in the 1980s, to 2,200 per year in
the 1990s.
There were 23,527 deaths due to colorectal
cancer in Iowa for the years 1973-2000 (Figure 1).
Deaths due to colorectal cancer have declined over
this period, from an average of 875 per year in the
1970s and 1980s to 790 in the 1990s. As shown in
Figure 2, colorectal cancer mortality rates have been
Colorectal Cancer
declining in Iowa since 1985 and are approaching the
goal set for the year 2010 in the statewide plan to
improve the health of Iowans, called Healthy Iowans
2010.
One of the keys to reducing death from
colorectal cancer is early detection. Staging is done
to determine whether the cancer has spread. Early
stage colorectal cancers are cancers that are generally
confined to the wall of the colon or rectum and have
not spread to the regional lymph nodes. As can be
seen in Figure 3, during the 1990s, 39 (males) and 37
(females) out of every 100 newly diagnosed colorectal
cancers were early stage. This has not changed much
since the 1970s where 33 (males) and 31 (females) out
of every 100 were early stage.
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Figure 1
Newly Diagnosed In Situ and Malignant Colorectal Cancers and Cancer Deaths
Iowa, 1973-2000
Black numbers: Newly diagnosed in situ and malignant colorectal cancers
Orange numbers: Colorectal cancer deaths
7Figure 3
Newly Diagnosed Colorectal Cancers and Female Breast Cancers by Stage
Iowa, 1973-1999
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The percentage of female and male colorectal cancers diagnosed at an
early stage have slowly increased over the last three decades, however they lag far
 behind the percentage of female breast cancers diagnosed at an early stage.
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Figure 2
Colorectal Cancer Incidence and Mortality Rates*
Iowa, 1973-2000
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8Screening tests can prevent the occurrence
of colorectal cancer by detecting and removing
adenomatous polyps before they become cancerous,
or they can identify cancer at an early stage, resulting
in better survival. Figure 4 shows relative survival
rates based on a modified version of the American
Joint Committee on Cancer’s staging classification.
Stage 0 tumors do not yet invade the wall of the colon,
Stage I tumors invade into or slightly through the wall,
and Stage II tumors invade more extensively and may
involve adjacent organs. Stage III represents regional
lymph node involvement. Stage IV represents distant
metastasis, such as spread of the cancer to the liver.
The graph shows that as the stage of disease pro-
gresses, the survival rates decrease. Five-year survival
rates are 98% for Stage 0, 94% for Stage I, and 83%
for Stage II. Thereafter, they decrease to 60% for Stage
III and 6% for Stage IV disease.
The American Cancer Society recommends
that beginning at age 50, both men and women
should follow one of these five screening options:
• a fecal occult blood test (FOBT) every year, or *
• flexible sigmoidoscopy every 5 years, or
• a fecal occult blood test every year plus flexible
sigmoidoscopy every 5 years, or *
(Of these first three options, the American Cancer Society
recommends option 3, i.e., FOBT every year and flexible
sigmoidoscopy every 5 years)
• Double-contrast barium enema every 5 to 10 years, or
• Colonoscopy every 10 years
* For FOBT, the take-home multiple sample method should
be used.
The large intestine (colon) is about 5-6 feet
long and is arbitrarily divided into several contiguous
segments. It begins at its connection to the small
intestine (ileocecal valve and cecum) in the right
lower abdomen, extends upward (ascending colon)
to the liver (hepatic flexure), across the upper
abdomen (transverse colon) to the spleen (splenic
flexure), down the left side of the abdomen (de-
scending colon) to an s-shaped segment (sigmoid)
in the pelvis, terminating in the rectum, the final 8-
10 inches. The terms “right” and “left” are often used
in referring to the colon, the right colon being the
portion from the ileocecal valve to the splenic flexure,
and the left from the splenic flexure to the rectum.
In the 1970’s, 36% of colorectal cancers were diag-
nosed in the right side. In the 1990’s, that percentage
has increased to 43%. It is not clear if this is due to
more effective screening of the right side (colon-
oscopy allows a view of the entire large intestine
whereas sigmoidoscopy reaches only the left side) or
if there is a true increase in right-sided cancers.
Despite the benefits and availability of
screening, there remain substantial portions of
Iowans who have never had a screening exam for
colorectal cancer (see Figure 5). This can be seen for
both use of the fecal occult blood test as well as a
sigmoidoscopy or colonoscopy. As shown in Figure 3,
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Figure 4
Relative Survival Rates for Colorectal Cancer by
SEER Modified AJCC Stage, Iowa 1990-1999
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Figure 5
Percent of Population Reporting about
Colorectal Cancer Screening, Iowa, 1999
during the 1990s, 69% of breast cancers were
diagnosed at an early stage. This is much higher than
the 39% and 37% seen with male and female colo-
rectal cancer, respectively. Mammography is the
screening tool available for the early detection of
breast cancer.  Whereas 13.4% of women 65 years of
age and older had not had a mammogram in 1999,
43.2% of Iowans of the same age had not had a
fecal occult blood test and 47.1% had not had a
sigmoidoscopy or colonoscopy for colorectal cancer.
Possible new screening methods are being
investigated. These include virtual colonoscopy, a
test that uses a Computer Assisted Tomography (CAT)
scanner with image processing computers, allowing
radiologists to view a 3-D image of the inner surface
of the colon. Another method uses stool based DNA
testing. Preliminary study findings show that this
screening test may spot colon cancers and polyps
early enough to make a real impact on survival.
The test measures DNA markers from an individual’s
stool sample that are specific to cancerous and pre-
cancerous cells.
Risk factors for colorectal cancer other than
age include a strong family history of colorectal cancer
or adenomatous polyps in a first-degree relative (in a
parent, sibling, or child before age 60 or in two first-
degree relatives at any age); a personal history of
colorectal cancer, polyps, or chronic inflammatory
bowel disease; or a family history of hereditary
colorectal cancer syndrome (e.g., familial adeno-
matous polyposis or hereditary non-polyposis colo-
rectal cancer). Screening should be considered earlier
than age 50 for people with any of these risk factors.
Physical inactivity and obesity have been
shown to increase one’s risk for colorectal cancer.
Red meat consumption, smoking, and drinking more
than one alcoholic drink per day are also associated
with an increased risk of colorectal cancer.
Current American Cancer Society recom-
mendations for nutrition and physical activity relevant
to colorectal cancer prevention include:
• Eat a variety of healthful foods, with an emphasis
on plant sources.
• Adopt a physically active lifestyle.
• Maintain a healthful weight throughout life.
• If you drink alcoholic beverages, limit consumption.
With increased utilization of the available
screening exams for colorectal cancer, we can
improve our percentage diagnosed at an early stage,
resulting in better treatment options and better
survival. The State Health Registry of Iowa has been
working with the state of Iowa on a Comprehensive
Cancer Control Plan, which addresses colorectal
cancer screening issues.
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questions, other resources (internet & telephone) for
agricultural health information, references for
publications to date, and information for scientific
collaborators can be found at the website: www.
aghealth.org.
BREAST CANCER, RADIATION EXPOSURE, AND GENETIC
SUSCEPTIBILITY
The objective of this study is to investigate gene-
environment interactions in the etiology of breast
cancer. We are establishing a repository of epidemi-
ologic risk factor information and biologic specimens
for a targeted goal of 700 women with asynchronous
bilateral breast cancer and 1400 women with uni-
lateral breast cancer, who are being ascertained
through 5 population-based tumor registries in the
U.S. and Denmark, including the Iowa Cancer Registry.
All subjects are being interviewed using a structured
questionnaire and blood samples are being collected
for genetic analyses. Initially, we will examine the
interaction of radiation exposure, the ATM gene, and
breast cancer. Ionizing radiation is known to be a
breast carcinogen and recent studies suggest that
the ATM gene may increase susceptibility to
radiation-induced breast cancer. Our hypothesis is
that women who are ATM gene carriers and who
have received radiation therapy as part of breast
cancer treatment are at an especially high risk of
developing a second primary breast cancer. We will
also provide descriptive statistics on the prevalence
of ATM in this large population-based sample of
women. Thereafter, we will determine the prevalence
of BRCA1 and BRCA2 mutations in this population
and evaluate interactions between breast cancer,
BRCA1/2 and ATM genetic mutations, and radiation
exposure. Iowa’s goal is to contribute 125 cases and
250 controls.
The State Health Registry of Iowa is participating
in over two dozen funded studies during 2003. Brief
descriptions of a few of these studies are provided.
THE AGRICULTURAL HEALTH STUDY
The Agricultural Health Study is a long-term study of
agricultural exposures and chronic disease
(especially cancer) among commercial or private
pesticide applicators (and their spouses, if married)
in Iowa and North Carolina. The study is funded
primarily by the National Cancer Institute. We are in
the eleventh year of the study.
In the first five years, 89,658 subjects (58,564
in Iowa and 31,094 in North Carolina) were enrolled
in the study. This total for Iowa included 31,877
private applicators, 21,771 spouses of private appli-
cators, and 4,916 commercial applicators. Currently,
we are in the second phase of the study, which
involves a telephone interview, a mailed dietary
questionnaire, and a cheek cell sample. The
telephone interview asks about pesticide use since
enrollment, current farming and work practices, and
health changes. The dietary health questionnaire asks
about cooking practices and types of foods eaten.
Cooking practices and diet may play a role in cancer
and other health conditions. The cheek cells will be
used to understand possible links between genetics,
exposures, and disease. Since 1997, cohort members
have been linked annually to mortality and cancer
registry incidence databases in both states. In
addition, mortality data on the cohort is being
obtained every other year from the National Death
Index. More information about recent results from
this study, the study background, frequently asked
Research Projects During 2003
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DATA COLLECTION OF ALL INTRACRANIAL AND
CENTRAL NERVOUS SYSTEM (CNS) NEOPLASMS
The primary objective of this study is to evaluate
the amount of extra work, quality control, training
and resources that will be needed when benign/
uncertain behavior brain/CNS tumors are collected
routinely for Iowans through the Iowa Cancer
Registry. A secondary objective is to obtain laterality
information (i.e., right or left side, where applicable)
for our malignant and benign/uncertain behavior
brain/CNS tumors. Initial results show that menin-
giomas, pituitary adenomas, and schwannomas will
account for the majority of benign brain tumors.
FEASIBILITY OF RETRIEVAL AND STORAGE OF TISSUE
BLOCKS FOR CANCER PATIENTS
Researchers affiliated with SEER Registries are
increasingly collecting biologic samples from cancer
patients. Pathology material should be available
retrospectively, but SEER registries are discovering
that for an ever-increasing number of cancer patients,
the material is being discarded by the originating
pathology labs. Thus, this is a real problem that
seriously impacts the population representativeness
of these studies. The overall goal of this study is to
continue an ongoing effort to have greater access
to tumor and non-tumor tissue related to the diag-
nosis and/or treatment of cancer so that there is
more representation of the population served by
the Registry.
IOWA AND MISSOURI RADON LUNG CANCER STUDIES
This study extends research on cases and controls
who are participating in studies of residential radon
and lung cancer in Iowa and Missouri. In this study,
we are deriving more accurate retrospective radon
dose estimates by using a novel retrospective radon
progeny-integrating glass-based detector. We are
determining whether exposure to residential radon
progeny is associated with an increase of lung cancer
and whether the shape of the dose-response curve
that best describes the relationship between res-
idential radon progeny exposure and lung cancer is
linear or nonlinear. Finally, we are evaluating whether
exposure to residential radon progeny is associated
with specific morphologic types of lung cancer, such
as adenocarcinoma.
LUNG CANCER CARE OUTCOMES/SURVEILLANCE
CONSORTIUM
This study involves a coordinating center, the Iowa
Cancer Registry, and five other primary data collection
and research sites across the United States. Across
these sites, we will investigate patterns of care for lung
cancer, the reasons for particular care decisions by
patients and their physicians, variation in dissem-
ination of modern care protocols and practices in
different geographic areas, and the effects of these
decisions and practices on patient outcomes, includ-
ing quality of life. In Iowa, we plan to rapidly identify
and enroll 1,000 lung cancer patients newly diagnosed
over an 18-month period beginning Spring 2003.
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OBESITY, RENAL CELL CARCINOMA (RCC) & EXPRESSION
OF THE INSULIN-LIKE GROWTH FACTOR-I RECEPTOR
This investigation will be conducted using RCC cases
from the Cancer and Drinking Water Contaminants
Study, a population-based case-control investigation
of six cancer sites previously conducted in Iowa.
The goal of this study is to determine whether the
association between obesity and development of
RCC is dependent on expression of the IGF-I receptor.
We are retrieving tumor blocks, where available, for
406 incident RCC cases in Iowa first diagnosed
between 1985 and 1987. Diagnostic slides and path-
ology reports will be reviewed in order to stage and
grade the tumors as well as to select appropriate
tumor cores from paraffin blocks. Tumor blocks will
be processed in the Mayo Tissue Acquisition and
Processing Core. We will identify the presence of
IGF-I receptor in the tumor tissue using immuno-
histochemical methods, thus allowing us to estimate
the prevalence of IGF-I receptor expression.
EPIDEMIOLOGICAL AND MEDICAL MONITORING
PROPOSAL OF FORMER DEPARTMENT OF DEFENSE
WORKERS AT THE IOWA ARMY AMMUNITION PLANT IN
MIDDLETOWN, IOWA
This study aims to conduct an epidemiologic survey
of occupational health outcomes and needs for
individuals employed by the Department of Defense
contractor, the Iowa Army Ammunition Plant in
Middletown, Iowa. The targeted employees worked
in conventional weapons manufacture on what was
known as Division A, which has been in operation
from 1945 to the present. Historical exposure assess-
ment and medical surveillance data are being collect-
ed for these employees. The data are also being linked
to Iowa death tapes, Iowa drivers’ licenses, Medicare
files, and the Iowa Cancer Registry incidence database.
IMMUNOGENETIC DETERMINANTS OF NON-HODGKIN’S
LYMPHOMA (NHL) SURVIVAL
We propose to systematically test the hypothesis that
genes with functional, common variant polymor-
phisms involved in immune function and regulation
are associated with overall survival from NHL. Our
specific aims are to evaluate: 1) the association of
polymorphisms in selected immune-related genes
from four key pathways on NHL survival that include
genes encoding inflammatory and regulatory
cytokines, Th1/Th2 cytokines, innate immunity, and
chemokines; 2) whether any effects are independent
of other NHL prognostic factors (such as age and
stage) and treatment modality; and 3) whether any
effects are specific to diffuse large B-cell lymphoma
or the combination of follicular and small lymph-
ocytic lymphoma. To achieve these aims, we will
develop a prognostic cohort from 364 HIV-negative
NHL patients who participated in the last few years
in a population-based case-control study in Iowa.
COOPERATIVE AGREEMENTS AND OTHER REGISTRIES
The State Health Registry of Iowa maintains
cooperative agreements with several hospital cancer
registries and other agencies. Some of these include:
• Iowa Department of Public Health
• The University of Iowa
- Birth Defects Registry of Iowa
- Center for Health Effects of Environmental
  Contamination
- Injury Prevention Research Center
- Environmental Health Sciences Research Center
- Iowa Center for Agricultural Safety and Health
- Prevention Intervention Center
- Holden Comprehensive Cancer Center
- Center for Public Health Statistics
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